Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study

NCT ID: NCT01859481

Last Updated: 2021-01-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

971 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-03-31

Study Completion Date

2002-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of headache response at 2 hours for active treated attacks for increasing dose.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine Without Aura Migraine With Aura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Eletriptan HBr 40 mg

Group Type EXPERIMENTAL

Eletriptan HBr 40 mg

Intervention Type DRUG

All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Eletriptan HBr 80 mg

Group Type EXPERIMENTAL

Eletriptan HBr 80 mg

Intervention Type DRUG

All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Intervention Type DRUG

Eletriptan HBr 40 mg

All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Intervention Type DRUG

Eletriptan HBr 80 mg

All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and Female subjects in good general health, aged 18 to 65 years.
* Subjects should meet IHS diagnostic criteria for migraine with or without aura.
* Based on past history, subjects should expect to suffer at least one acute attack of migraine with or without aura, each 6 weeks

Exclusion Criteria

* Known coronary-artery disease, clinically significant arrhythmia, heart failure, or uncontrolled hypertension.
* Pregnant or lactating women.
* Clinically significant electrocardiogram abnormalities at screening.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eeuwfeestkliniek

Antwerp, , Belgium

Site Status

A.Z. Sint Jan

Bruges, , Belgium

Site Status

Cliniques Universitaires St Luc

Brussels, , Belgium

Site Status

C.H.U. de Charleroi

Charleroi, , Belgium

Site Status

Hopital de La Citadelle

Liège, , Belgium

Site Status

Faculty Hospital U Svety Anny

Brno, , Czechia

Site Status

Neurologika Klinika F.N.

Hradec Králové, , Czechia

Site Status

Pain Centrum

Prague, , Czechia

Site Status

1St Medical Faculty of the Charles University

Prague, , Czechia

Site Status

Arhus Kommunehospital

Arhus C, , Denmark

Site Status

Kas Glostrup

Glostrup Municipality, , Denmark

Site Status

Korsgaard, Anne G. (Private Practice)

Odense C, , Denmark

Site Status

Asbjorn Ziebel

Roskilde, , Denmark

Site Status

Peter Staehr

Ølstykke, , Denmark

Site Status

Hopital de Rangueil

Toulouse, Cedex 04, France

Site Status

Veyrie-Courtade

Toulouse, Tououse, France

Site Status

C.H.U.R Bretonneau

Tours, Tours, France

Site Status

Kubler Altkirch

Altkirch, , France

Site Status

Marcombes Angouleme

Angoulême, , France

Site Status

Houdart Anzin

Anzin, , France

Site Status

Groupe Pellegrin Tripode

Bordeaux, , France

Site Status

Siboni Carcassonne

Carcassonne, , France

Site Status

Hopital Louis Mourier

Colombes, , France

Site Status

Cormier Laval

Laval, , France

Site Status

Hopital Salengro

Lille, , France

Site Status

Hopital Louis Pradel

Lyon, , France

Site Status

Hopital Pasteur

Nice, , France

Site Status

Private Practice

Orléans, , France

Site Status

Delfiner Paris

Paris, , France

Site Status

Hopital Lariboisiere

Paris, , France

Site Status

Hopital Cochin

Paris Codex 14, , France

Site Status

Vaunaize Reims (Ds For Oc)

Reims, , France

Site Status

Vaunaize Reims

Reims, , France

Site Status

Hopital Charles Nicolle

Rouen, , France

Site Status

Hospital Bellevue

Saint-Etienne, , France

Site Status

Bouchacourt Toulon

Toulon, , France

Site Status

Lemarquis Toulon

Toulon, , France

Site Status

Mick Voiron

Voiron, , France

Site Status

Private Practice

Berlin, , Germany

Site Status

Private Practice

Berlin, , Germany

Site Status

Private Practice (Guenther Schumann)

Bochum, , Germany

Site Status

Private Practice

Bochum, , Germany

Site Status

Private Practice

Eckernförde, , Germany

Site Status

Private Practice

Göttingen, , Germany

Site Status

Private Practice

Hamburg, , Germany

Site Status

Private Practice

Oldenburg, , Germany

Site Status

Fachklinik Fuer Neurologie Dietenbronn Gmbh

Schwendi, , Germany

Site Status

Private Practice (Dr. Renate Kreyer)

Stade, , Germany

Site Status

Neurology Clinic of Chania

Soúda, Chania,crete, Greece

Site Status

General Athens State Hospital

Athens, , Greece

Site Status

Saint Dimitrios Hospital

Thessaloniki, , Greece

Site Status

Peterfy Teaching Hospital

Budapest, , Hungary

Site Status

Semmelweis University

Budapest, , Hungary

Site Status

Szent-Imre Hospital

Budapest, , Hungary

Site Status

Jahn Ferenc Hospital

Budapest, , Hungary

Site Status

Uzsoki Hospital

Budapest, , Hungary

Site Status

University of Debrecen, Medical and Health Science Centre, Medical School

Debrecen, , Hungary

Site Status

Kenezy County Hospital

Debrecen, , Hungary

Site Status

Universita Degli Studi Di Modena-Policlinico Dipartimento Di Medicina Interna

Modena, Emilia-Romagna, Italy

Site Status

Fondazione Istituto Neurologico Casimiro Mondino Istituto Di Ricovero E Cura A Carattere Scientifico

Pavia, Lombardy, Italy

Site Status

Universita' Di Bologna

Bologna, , Italy

Site Status

Poliambulatorio Salus

Brescia, , Italy

Site Status

Universita' Degli Studi Di Cagliari - Presidio Osp.S.Giovanni Di Dio

Cagliari, , Italy

Site Status

Azienda Vittorio Emanuele

Catania, , Italy

Site Status

Clinica Neurologica

L'aquila-coppito, , Italy

Site Status

Policlinico Universitario

Messina, , Italy

Site Status

Centro Cefalee Irccs "C. Besta"

Milan, , Italy

Site Status

Universita Di Padova

Padua, , Italy

Site Status

Centro Cefalee

Parma, , Italy

Site Status

Clinica Neurologica, Universita Di Perugia

Perugia, , Italy

Site Status

Centro Cefalee - Neuromed

Pozzilli (isernia), , Italy

Site Status

Ospedale S. Eugenio

Roma, , Italy

Site Status

Centro Cefalee

Torino, , Italy

Site Status

Ospedale Regionale Torrette

Torrette DI Ancona (AN), , Italy

Site Status

Ospedale Maggiore

Trieste, , Italy

Site Status

Ospedale S. Bortolo

Vicenza, , Italy

Site Status

Bosch Medicentrum (Locatie Willem Alexander Ziekenhuis)

's-Hertogenbosch, , Netherlands

Site Status

Sint Lucas Andreas Ziekenhuis (Location: St.Lucas)

Amsterdam, , Netherlands

Site Status

Gelre Ziekenhuis (Location: Lukas)

Apeldoorn, , Netherlands

Site Status

Ziekenhuis Gooi-Noord

Blaricum, , Netherlands

Site Status

Ignatius Ziekenhuis Breda

Breda, , Netherlands

Site Status

Gelderse Vallei Ziekenhuis

Ede, , Netherlands

Site Status

Scheperziekenhuis

Emmen, , Netherlands

Site Status

Atrium Heerlen

Heerlen, , Netherlands

Site Status

St. Streekziekenhuis Midden Twente

Hengelo (OV), , Netherlands

Site Status

Ikazia Ziekenhuis

Rotterdam, , Netherlands

Site Status

Sint Elisabeth Ziekenhuis

Venray, , Netherlands

Site Status

Lage Land Ziekenhuis

Zoetermeer, , Netherlands

Site Status

Sentralsykehuset I Akershus

Nordbyhagen, , Norway

Site Status

Volvat Medisinske Senter

Oslo, , Norway

Site Status

Strandquist, Dr. Stein Bror

Tønsberg, , Norway

Site Status

Hospital Garcia Da Orta

Almada, , Portugal

Site Status

Centro Hospitalar de Coimbra

Coimbra, , Portugal

Site Status

Hospital S.Joao

Porto, , Portugal

Site Status

Consorci Hospitalari Del Parc Tauli

Sabadell, Barcelona, Spain

Site Status

Hospital Universitario de Puerto Real

Puerto Real, Cadiz, Spain

Site Status

Fundacion Hospital Alcorcon

Alcorcón, Madrid, Spain

Site Status

Hospital de Galdakao

Galdakao, Vizcaya, Spain

Site Status

Hospital Torrecardenas

Almería, , Spain

Site Status

Hospital Del Sagrado Corazon

Barcelona, , Spain

Site Status

Hospital General Universitari Vall D�Hebron

Barcelona, , Spain

Site Status

Hospital General Yag�

Burgos, , Spain

Site Status

Hospital Nuestra SE�Ra de Alarcos

Ciudad Real, , Spain

Site Status

Hospital Na Sa de Aranzazu

Donostia / San Sebastian, , Spain

Site Status

Hospital Ciudad de Jaen

Jaén, , Spain

Site Status

Hospital Universitari de Lleida Arnau de Vilanova

Lleida, , Spain

Site Status

Hospital Ramon Y Cajal

Madrid, , Spain

Site Status

Hospital Universitario San Carlos

Madrid, , Spain

Site Status

Hospital Virgen de La Victoria

Málaga, , Spain

Site Status

Hospital General Universitario J. M. Morales Meseguer

Murcia, , Spain

Site Status

Hospital General de Asturias

Oviedo, , Spain

Site Status

Hospital Nuestra SE�Ra de Valme

Seville, , Spain

Site Status

Hospital Clinico Universitario La Fe

Valencia, , Spain

Site Status

Hospital General Universitario

Valencia, , Spain

Site Status

Fritsla Vardcentral

Fritsla, , Sweden

Site Status

Migranklinik-Goeteborg

Gothenburg, , Sweden

Site Status

Lanssjukhuset Halmstad

Halmstad, , Sweden

Site Status

Viktoriakliniken

Halmstad, , Sweden

Site Status

Neurologsektionen, Lasarettet

Helsingborg, , Sweden

Site Status

Neuro Kliniken, Helsingborg

Helsingborg, , Sweden

Site Status

Sjocrona Vardcentral

Höganäs, , Sweden

Site Status

Huddinge Universitetssjukhus

Huddinge, , Sweden

Site Status

Kistahalsan Ab

Kista, , Sweden

Site Status

Lund Lakarmottagningen

Lund, , Sweden

Site Status

Medicin Kliniken, Universitetssjukhuset

Lund, , Sweden

Site Status

Lakargruppen Gustaf Adolf

Malmo, , Sweden

Site Status

Previa Ab Sigtunahalsan

Märsta, , Sweden

Site Status

Oxelohalsan

Oxelösund, , Sweden

Site Status

Bankhalsan

Stockholm, , Sweden

Site Status

Lakarhuset Odenplan

Stockholm, , Sweden

Site Status

Ostermalmshalsan

Stockholm, , Sweden

Site Status

St Gorans Sjukhus

Stockholm, , Sweden

Site Status

Tyresohalsan Huslakare Ab (Ds For Oc)

Tyreso, , Sweden

Site Status

Tyresohalsan Huslakare Ab

Tyreso, , Sweden

Site Status

Kronobergskliniken

Vaxjo, , Sweden

Site Status

Centrallasarettet

Västerås, , Sweden

Site Status

Vasterviks Sjukhus

Västervik, , Sweden

Site Status

Novakliniken

Ystad, , Sweden

Site Status

Cukurova University Medical Faculty

Adana, , Turkey (Türkiye)

Site Status

Karadeniz Technical University Medical Faculty

Trabzon, , Turkey (Türkiye)

Site Status

Ahepa University Hospital

, ,

Site Status

Foretagshalsovarden Linden

, ,

Site Status

Huslakargruppen

, ,

Site Status

Limhamns Lakargrupp, Tarnan

, ,

Site Status

Medicinskt Centrum

, ,

Site Status

Sentralsjukehuset I Hedmark

, ,

Site Status

Sint Anna Ziekenhuis

, ,

Site Status

Vardcentralen

, ,

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Czechia Denmark France Germany Greece Hungary Italy Netherlands Norway Portugal Spain Sweden Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. Cephalalgia. 2014 Feb;34(2):126-35. doi: 10.1177/0333102413500726. Epub 2013 Aug 14.

Reference Type DERIVED
PMID: 23946318 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A1601015

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BI 44370 TA in Acute Migraine Attack
NCT00751803 COMPLETED PHASE2